U.S. Markets closed

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MMM, RBGLY, OMCL and EGBN

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

3M Company (MMM)
Class Period: February 9, 2017 to May 28, 2019
Lead Plaintiff Deadline: September 27, 2019

According to the complaint, 3M Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances (“PFAS”) are toxic (which was first publicly revealed in February 2018 by Minnesota’s Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.

Get additional information about the MMM lawsuit: http://www.kleinstocklaw.com/pslra-1/3m-company-loss-submission-form?wire=3

Reckitt Benckiser Group plc (RBGLY)
Class Period: On behalf of all purchasers of Reckitt American Depositary Shares (“ADSs”) from July 28, 2014 through April 9, 2019
Lead Plaintiff Deadline: September 13, 2019

The lawsuit alleges that Reckitt Benckiser Group plc made materially false and/or misleading statements and/or failed to disclose that: (a) defendants had engaged in a scheme to artificially inflate the sales of Suboxone Film by more than $3 billion by falsely touting the drug’s purportedly superior efficacy and safety as compared to tablets; (b) contrary to defendants’ public statements, the FDA and internal Company documents had concluded that Suboxone Film posed a potentially greater risk of abuse and child endangerment than other available treatments; (c) defendants had fabricated a safety scare involving Suboxone Tablets in order to unlawfully delay and prevent generic competition; (d) defendants had engaged in a massive marketing campaign that had misrepresented the purported benefits of Suboxone Film as compared to Suboxone Tablets to doctors, healthcare providers, government regulators and investors; (e) defendants had encouraged Suboxone sales through medical providers that they knew were overprescribing the drug, facilitating the drug’s abuse and/or prescribing it in a careless and clinically unwarranted manner, often to hundreds of individuals at a time; (f) as a result of (a)-(e) above, Reckitt’s revenues, net income an d earnings were artificially inflated and the product of illicit business practices; and (g) as a result of (a)-(f) above, Reckitt and Reckitt Pharma were exposed to extraordinary undisclosed legal and reputational risks that could result in billions of dollars in fines, lost business and legal judgments or other monetary penalties.

Get additional information about the RBGLY lawsuit: http://www.kleinstocklaw.com/pslra-1/reckitt-benckiser-group-plc-loss-submission-form?wire=3

Omnicell, Inc. (OMCL)
Class Period: October 25, 2018 to July 11, 2019
Lead Plaintiff Deadline: September 16, 2019

During the class period, Omnicell, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the Company recognized revenue for certain transactions before fulfilling its performance obligations; (2) the Company engaged in improper accounting practices to meet revenue targets; (3) the Company experienced weaker demand for new product lines than it had previously projected; (4) as a result, the Company would be required to write-off certain inventory; (5) the Company misclassified certain expenses as capitalized expenditures; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the OMCL lawsuit: http://www.kleinstocklaw.com/pslra-1/omnicell-inc-loss-submission-form?wire=3

Eagle Bancorp, Inc. (EGBN)
Class Period: March 2, 2015 to July 17, 2019
Lead Plaintiff Deadline: September 23, 2019

The lawsuit alleges that Eagle Bancorp, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Get additional information about the EGBN lawsuit: http://www.kleinstocklaw.com/pslra-1/eagle-bancorp-inc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com